Matsushita Kazuyuki, Kitamura Kouichi, Rahmutulla Bahityar, Tanaka Nobuko, Ishige Takayuki, Satoh Mamoru, Hoshino Tyuji, Miyagi Satoru, Mori Takeshi, Itoga Sakae, Shimada Hideaki, Tomonaga Takeshi, Kito Minoru, Nakajima-Takagi Yaeko, Kubo Shuji, Nakaseko Chiaki, Hatano Masahiko, Miki Takashi, Matsuo Masafumi, Fukuyo Masaki, Kaneda Atsushi, Iwama Atsushi, Nomura Fumio
Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Division of Laboratory Medicine, Chiba University Hospital, Inohana, Chiba, Japan.
Oncotarget. 2015 Mar 10;6(7):5102-17. doi: 10.18632/oncotarget.3244.
FUSE-binding protein (FBP)-interacting repressor (FIR) is a c-myc transcriptional suppressor. A splice variant of FIR that lacks exon 2 in the transcriptional repressor domain (FIRΔexon2) upregulates c-myc transcription by inactivating wild-type FIR. The ratio of FIRΔexon2/FIR mRNA was increased in human colorectal cancer and hepatocellular carcinoma tissues. Because FIRΔexon2 is considered to be a dominant negative regulator of FIR, FIR heterozygous knockout (FIR⁺/⁻) C57BL6 mice were generated. FIR complete knockout (FIR⁻/⁻) was embryonic lethal before E9.5; therefore, it is essential for embryogenesis. This strongly suggests that insufficiency of FIR is crucial for carcinogenesis. FIR⁺/⁻ mice exhibited prominent c-myc mRNA upregulation, particularly in the peripheral blood (PB), without any significant pathogenic phenotype. Furthermore, elevated FIRΔexon2/FIR mRNA expression was detected in human leukemia samples and cell lines. Because the single knockout of TP53 generates thymic lymphoma, FIR⁺/⁻TP53⁻/⁻ generated T-cell type acute lymphocytic/lymphoblastic leukemia (T-ALL) with increased organ or bone marrow invasion with poor prognosis. RNA-sequencing analysis of sorted thymic lymphoma cells revealed that the Notch signaling pathway was activated significantly in FIR⁺/⁻TP53⁻/⁻ compared with that in FIR⁺/⁺TP53⁻/⁻ mice. Notch1 mRNA expression in sorted thymic lymphoma cells was confirmed using qRT-PCR. In addition, flow cytometry revealed that c-myc mRNA was negatively correlated with FIR but positively correlated with Notch1 in sorted T-ALL/thymic lymphoma cells. Moreover, the knockdown of TP53 or c-myc using siRNA decreased Notch1 expression in cancer cells. In addition, an adenovirus vector encoding FIRΔexon2 cDNA increased bleomycin-induced DNA damage. Taken together, these data suggest that the altered expression of FIRΔexon2 increased Notch1 at least partially by activating c-Myc via a TP53-independent pathway. In conclusion, the alternative splicing of FIR, which generates FIRΔexon2, may contribute to both colorectal carcinogenesis and leukemogenesis.
FUSE结合蛋白(FBP)相互作用阻遏物(FIR)是一种c-myc转录抑制因子。转录抑制结构域中缺失外显子2的FIR剪接变体(FIRΔexon2)通过使野生型FIR失活而上调c-myc转录。在人类结直肠癌和肝细胞癌组织中,FIRΔexon2/FIR mRNA的比例增加。由于FIRΔexon2被认为是FIR的显性负调控因子,因此构建了FIR杂合敲除(FIR⁺/⁻)C57BL6小鼠。FIR完全敲除(FIR⁻/⁻)在E9.5之前胚胎致死;因此,它对胚胎发育至关重要。这强烈表明FIR功能不足对肿瘤发生至关重要。FIR⁺/⁻小鼠表现出显著的c-myc mRNA上调,特别是在外周血(PB)中,且无任何明显的致病表型。此外,在人类白血病样本和细胞系中检测到FIRΔexon2/FIR mRNA表达升高。由于TP53单敲除会产生胸腺淋巴瘤,FIR⁺/⁻TP53⁻/⁻产生T细胞型急性淋巴细胞/淋巴母细胞白血病(T-ALL),器官或骨髓浸润增加,预后不良。对分选的胸腺淋巴瘤细胞进行RNA测序分析显示,与FIR⁺/⁺TP53⁻/⁻小鼠相比,FIR⁺/⁻TP53⁻/⁻小鼠的Notch信号通路被显著激活。使用qRT-PCR证实了分选的胸腺淋巴瘤细胞中Notch1 mRNA的表达。此外,流式细胞术显示,在分选的T-ALL/胸腺淋巴瘤细胞中,c-myc mRNA与FIR呈负相关,但与Notch1呈正相关。此外,使用siRNA敲低TP53或c-myc可降低癌细胞中Notch1的表达。此外,编码FIRΔexon2 cDNA的腺病毒载体增加了博来霉素诱导的DNA损伤。综上所述,这些数据表明,FIRΔexon2表达的改变至少部分通过不依赖TP53的途径激活c-Myc来增加Notch1。总之,产生FIRΔexon2的FIR可变剪接可能在结直肠癌发生和白血病发生中都起作用。